Table 1. Clinical trials evaluating osimertinib.

Study ref	Treatment	No. of patients	ORR	PFS (months)
AURA 1 (phase 1) (12)	Osimertinib	127 T790M+	61% (52–70%)	9.6 (8.3–NR)
AURA2 (phase 2) (13)	Osimertinib	210 T790M+	70% (64–77%)	9.9 (8.5–12.3)
AURA 3 (phase 3) (14)	Osimertinib vs. platinum-pemetrexed	419 T790M+	71 vs. 31, OR 5.39 (95% CI, 3.47–8.48), P<0.001	10.1 vs. 4.4, HR 0.30 (95% CI, 0.23–0.41), P<0.001
FLAURA (phase 3) (15)	Osimertinib vs. gefitinib or erlotinib	556 naive	80 vs. 76, OR 1.27 (95% CI, 0.85–1.90), P=0.24	18.9 vs. 10.2, HR 0.46 (95% CI, 0.37–0.57), P<0.001

ORR, objective response rate; OR, odds ratio; CI, confidence interval; PFS, progression free survival; HR, hazard ratio; NR, not reached.